Lead Product(s) : Saroglitazar magnesium
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Aims to Launch First New Drug in US by Early 2026
Details : Saroglitazar is a first in class drug which acts as a dual PPAR agonist at the subtypes α (alpha) and γ (gamma). It is being evaluated for the treatment of Primary Biliary Cholangitis.
Product Name : Lipaglyn
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 27, 2024
Lead Product(s) : Saroglitazar magnesium
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Belapectin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GR-MD-02 (Belapectin) is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of NASH and fibrosis. Belapectin binds to galectin-3 and disrupts its major role in diseases that involve scarring of organs, including f...
Product Name : GR-MD-02
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 01, 2023
Lead Product(s) : Belapectin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Belapectin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GR-MD-02 (belapectin) is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of NASH and fibrosis. Belapectin binds to galectin-3 and disrupts its major role in diseases that involve scarring of organs, including f...
Product Name : GR-MD-02
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 16, 2023
Lead Product(s) : Belapectin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Belapectin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GR-MD-02 (belapectin) is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of NASH and fibrosis. Belapectin binds to galectin-3 and disrupts its major role in diseases that involve scarring of organs, including f...
Product Name : GR-MD-02
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 10, 2023
Lead Product(s) : Belapectin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Belapectin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GR-MD-02 (belapectin) is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of NASH and fibrosis.Belapectin binds to galectin-3 and disrupts its role in diseases that involve scarring of organs.
Product Name : GR-MD-02
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 03, 2023
Lead Product(s) : Belapectin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Belapectin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Galectin Therapeutics to Present in Upcoming Conferences
Details : Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of NASH and fibrosis. Belapectin binds to galectin-3 and disrupts its function.
Product Name : GR-MD-02
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 14, 2022
Lead Product(s) : Belapectin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Belapectin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of NASH and fibrosis. Preclinical data in animals have shown that belapectin has robust treatment effects in reversing liver fibrosis and cirrhosis.
Product Name : GR-MD-02
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 14, 2022
Lead Product(s) : Belapectin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Setanaxib
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
First Patient Randomized in Pivotal TRANSFORM Study with Setanaxib
Details : The TRANSFORM Phase 2b/3 trial for GKT831 (setanaxib), a NOX1 and NOX4 inhibitor, will investigate the effect of setanaxib versus placebo on alkaline phosphatase reduction in patients with PBC also has shown evidence of anti-fibrotic activity in a Phase ...
Product Name : GKT137831
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 15, 2022
Lead Product(s) : Setanaxib
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Belapectin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GR-MD-02 (belapectin) is complex carbohydrate drug that targets galectin-3, a critical protein in pathogenesis of NASH and fibrosis also it binds to galectin-3 and disrupts its function.
Product Name : GR-MD-02
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 11, 2022
Lead Product(s) : Belapectin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Saroglitazar magnesium
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Announces EPICS-IIITM Phase 2(b)/3 Adaptive Pivotal Clinical Trial of Saroglitazar Mg in PBC
Details : Company announced that it has received permission from the USFDA to initiate the Phase 2(b)/3 clinical trial to evaluate efficacy and safety of Lipaglyn (Saroglitazar Magnesium) in subjects with PBC.
Product Name : Lipaglyn
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 12, 2021
Lead Product(s) : Saroglitazar magnesium
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable